Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Prostate Cancer

  Free Subscription


Articles published in Int J Urol

Retrieve available abstracts of 85 articles:
HTML format
Text format



Single Articles


    March 2017
  1. NARAYAN VM, Konety BR, Warlick C
    Novel biomarkers for prostate cancer: An evidence-based review for use in clinical practice.
    Int J Urol. 2017 Mar 27. doi: 10.1111/iju.13326.
    PubMed     Text format     Abstract available


    February 2017
  2. SHOJI S, Hiraiwa S, Ogawa T, Kawakami M, et al
    Accuracy of real-time magnetic resonance imaging-transrectal ultrasound fusion image-guided transperineal target biopsy with needle tracking with a mechanical position-encoded stepper in detecting significant prostate cancer in biopsy-naive men.
    Int J Urol. 2017 Feb 21. doi: 10.1111/iju.13306.
    PubMed     Text format     Abstract available


  3. EGEVAD L, Samaratunga H, Delahunt B
    Editorial Comment to Biopsy undergrading in men with Gleason score 6 and fatal prostate cancer in the European Randomized study of Screening for Prostate Cancer Rotterdam.
    Int J Urol. 2017 Feb 17. doi: 10.1111/iju.13305.
    PubMed     Text format    


  4. ALBERTS AR, Bokhorst LP, Kweldam CF, Schoots IG, et al
    Biopsy undergrading in men with Gleason score 6 and fatal prostate cancer in the European Randomized study of Screening for Prostate Cancer Rotterdam.
    Int J Urol. 2017 Feb 7. doi: 10.1111/iju.13294.
    PubMed     Text format     Abstract available


    January 2017
  5. KESCH C, Hadaschik BA, Radtke JP
    Editorial Comment to Assessing clinically significant prostate cancer: Diagnostic properties of multiparametric magnetic resonance imaging compared to three-dimensional transperineal template mapping histopathology.
    Int J Urol. 2017 Jan 13. doi: 10.1111/iju.13263.
    PubMed     Text format    


    December 2016
  6. FENG T, Howard LE, Vidal AC, Moreira DM, et al
    Serum cholesterol and risk of lower urinary tract symptoms progression: Results from the Reduction by Dutasteride of Prostate Cancer Events study.
    Int J Urol. 2016 Dec 22. doi: 10.1111/iju.13265.
    PubMed     Text format     Abstract available


    November 2016
  7. JAZAYERI SB, Samadi DB
    Prostate cancer in African Americans: Early oncological and functional outcomes after robotic prostatectomy.
    Int J Urol. 2016 Nov 16. doi: 10.1111/iju.13255.
    PubMed     Text format    


  8. TSIVIAN M, Gupta RT, Tsivian E, Qi P, et al
    Assessing clinically significant prostate cancer: Diagnostic properties of multiparametric magnetic resonance imaging compared to three-dimensional transperineal template mapping histopathology.
    Int J Urol. 2016 Nov 8. doi: 10.1111/iju.13251.
    PubMed     Text format     Abstract available


    October 2016
  9. RAMALINGAM S, Eisenberg A, Foo WC, Freedman J, et al
    Treatment-related neuroendocrine prostate cancer resulting in Cushing's syndrome.
    Int J Urol. 2016 Oct 21. doi: 10.1111/iju.13225.
    PubMed     Text format     Abstract available


  10. KRETSCHMER A, Gratzke C
    Editorial Comment to Treatment-related neuroendocrine prostate cancer resulting in Cushing's syndrome.
    Int J Urol. 2016 Oct 18. doi: 10.1111/iju.13239.
    PubMed     Text format    


  11. HENNING JD, Bonachea LA, Bunker CH, Patrick AL, et al
    Human herpesvirus 8 infection contributes to a T helper 2 immune response in men from Tobago with prostate cancer.
    Int J Urol. 2016 Oct 12. doi: 10.1111/iju.13243.
    PubMed     Text format     Abstract available


    September 2016
  12. OSAWA T, Wittmann D, Jimbo M, Keller ET, et al
    Providing prostate cancer survivorship care in Japan: Implications from the USA care model.
    Int J Urol. 2016 Sep 13. doi: 10.1111/iju.13186.
    PubMed     Text format     Abstract available


  13. SCHIAVINA R, Bianchi L, Borghesi M, Briganti A, et al
    Predicting survival in node-positive prostate cancer after open, laparoscopic or robotic radical prostatectomy: A competing risk analysis of a multi-institutional database.
    Int J Urol. 2016 Sep 12. doi: 10.1111/iju.13203.
    PubMed     Text format     Abstract available


    July 2016
  14. LIU CM, Hsieh CL, Shen CN, Lin CC, et al
    Exosomes from the tumor microenvironment as reciprocal regulators that enhance prostate cancer progression.
    Int J Urol. 2016 Jul 10. doi: 10.1111/iju.13145.
    PubMed     Text format     Abstract available


    June 2016
  15. PARIMI S, Chi KN
    Chemotherapy for metastatic castration-sensitive prostate cancer.
    Int J Urol. 2016 Jun 26. doi: 10.1111/iju.13148.
    PubMed     Text format     Abstract available


  16. SAKAMOTO S
    Editorial Comment to Androgen receptor targeted therapies in castration-resistant prostate cancer: Bench to clinic.
    Int J Urol. 2016 Jun 20. doi: 10.1111/iju.13147.
    PubMed     Text format    


  17. SAKAMOTO S
    Editorial Comment to Androgen receptor splice variant 7 in castration-resistant prostate cancer: Clinical considerations.
    Int J Urol. 2016 Jun 20. doi: 10.1111/iju.13146.
    PubMed     Text format    


  18. IMAMURA Y, Sadar MD
    Androgen receptor targeted therapies in castration-resistant prostate cancer: Bench to clinic.
    Int J Urol. 2016 Jun 14. doi: 10.1111/iju.13137.
    PubMed     Text format     Abstract available


  19. PORPIGLIA F, Cantiello F, De Luca S, De Pascale A, et al
    Multiparametric magnetic resonance imaging and active surveillance: How to better select insignificant prostate cancer?
    Int J Urol. 2016 Jun 9. doi: 10.1111/iju.13138.
    PubMed     Text format     Abstract available


  20. BRYCE AH, Antonarakis ES
    Androgen receptor splice variant 7 in castration-resistant prostate cancer: Clinical considerations.
    Int J Urol. 2016 Jun 3. doi: 10.1111/iju.13134.
    PubMed     Text format     Abstract available


    May 2016
  21. UENO Y, Tamada T, Bist V, Reinhold C, et al
    Multiparametric magnetic resonance imaging: Current role in prostate cancer management.
    Int J Urol. 2016 May 17. doi: 10.1111/iju.13119.
    PubMed     Text format     Abstract available


    April 2016
  22. SAKAMOTO S
    Editorial Comment to Current status of primary pharmacotherapy and future perspectives toward upfront therapy for metastatic hormone-sensitive prostate cancer.
    Int J Urol. 2016 Apr 17. doi: 10.1111/iju.13090.
    PubMed     Text format    


  23. SHIOTA M, Eto M
    Current status of primary pharmacotherapy and future perspectives toward upfront therapy for metastatic hormone-sensitive prostate cancer.
    Int J Urol. 2016 Apr 8. doi: 10.1111/iju.13091.
    PubMed     Text format     Abstract available


  24. MITSUZUKA K
    Editorial Comment to Prediagnostic prostate-specific antigen kinetics and the risk of biopsy progression in active surveillance patients.
    Int J Urol. 2016;23:317-8.
    PubMed     Text format    


  25. IREMASHVILI V, Barney SL, Manoharan M, Kava BR, et al
    Prediagnostic prostate-specific antigen kinetics and the risk of biopsy progression in active surveillance patients.
    Int J Urol. 2016;23:313-7.
    PubMed     Text format     Abstract available


    March 2016
  26. KIMURA G, Yonese J, Fukagai T, Kamba T, et al
    Enzalutamide in Japanese patients with chemotherapy-naive, metastatic castration-resistant prostate cancer: A post-hoc analysis of the placebo-controlled PREVAIL trial.
    Int J Urol. 2016 Mar 27. doi: 10.1111/iju.13072.
    PubMed     Text format     Abstract available


  27. MCGINLEY KF, Sun X, Howard LE, Aronson WJ, et al
    Utilization and impact of surgical technique on the performance of pelvic lymph node dissection at radical prostatectomy: Results from the Shared Equal Access Regional Cancer Hospital database.
    Int J Urol. 2016;23:241-6.
    PubMed     Text format     Abstract available


    February 2016
  28. SUN Y, Zou Q, Sun Z, Li C, et al
    Abiraterone acetate for metastatic castration-resistant prostate cancer after docetaxel failure: A randomized, double-blind, placebo-controlled phase 3 bridging study.
    Int J Urol. 2016 Feb 15. doi: 10.1111/iju.13051.
    PubMed     Text format     Abstract available


  29. BIRKELAND S
    Re: Prostate-specific antigen-based prostate cancer screening: Past and future.
    Int J Urol. 2016 Feb 2. doi: 10.1111/iju.13038.
    PubMed     Text format    


    January 2016
  30. GANDAGLIA G, Montorsi F, Briganti A
    Editorial Comment to Relationship between androgen deprivation therapy and community-acquired respiratory infections in patients with prostate cancer.
    Int J Urol. 2016 Jan 20. doi: 10.1111/iju.13046.
    PubMed     Text format    


  31. SCHMID M, Hanske J, Ravi P, Krishna N, et al
    Relationship between androgen deprivation therapy and community-acquired respiratory infections in patients with prostate cancer.
    Int J Urol. 2016 Jan 13. doi: 10.1111/iju.13043.
    PubMed     Text format     Abstract available


  32. SONG W, Jeon HG, Sung HH, Jeong BC, et al
    Prognostic factors after salvage radiotherapy alone in patients with biochemical recurrence after radical prostatectomy.
    Int J Urol. 2016;23:56-61.
    PubMed     Text format     Abstract available


    December 2015
  33. MATSUSHIMA M, Kikuchi E, Matsumoto K, Kosaka T, et al
    Erectile function status is highly associated with prostate-specific antigen bounce in localized prostate cancer patients treated with permanent prostate brachytherapy.
    Int J Urol. 2015 Dec 12. doi: 10.1111/iju.13029.
    PubMed     Text format     Abstract available


    November 2015
  34. ROMERO-OTERO J, Garcia-Gomez B, Duarte-Ojeda JM, Rodriguez-Antolin A, et al
    Active surveillance for prostate cancer.
    Int J Urol. 2015 Nov 30. doi: 10.1111/iju.13016.
    PubMed     Text format     Abstract available


    October 2015
  35. DE CASTRO ABREU AL, Ukimura O
    Editorial Comment to Validation of active surveillance criteria for pathologically insignificant prostate cancer in Asian men.
    Int J Urol. 2015 Oct 26. doi: 10.1111/iju.12994.
    PubMed     Text format    


  36. MIYATA Y, Sakai H
    Response to Re: Reconsideration of the clinical and histopathological significance of angiogenesis in prostate cancer: Usefulness and limitations of microvessel density measurement.
    Int J Urol. 2015 Oct 25. doi: 10.1111/iju.12997.
    PubMed     Text format    


  37. YAMADA Y, Sakamoto S, Sazuka T, Goto Y, et al
    Validation of active surveillance criteria for pathologically insignificant prostate cancer in Asian men.
    Int J Urol. 2015 Oct 8. doi: 10.1111/iju.12952.
    PubMed     Text format     Abstract available


  38. KAJIKAWA K, Kanao K, Kobayashi I, Nishikawa G, et al
    Optimal method for measuring tumor extent in needle biopsy specimens to identify small-volume prostate cancer.
    Int J Urol. 2015 Oct 8. doi: 10.1111/iju.12961.
    PubMed     Text format     Abstract available


    September 2015
  39. TAVERNA G, Cote R, Grizzi F
    Re: Reconsideration of the clinical and histopathological significance of angiogenesis in prostate cancer: Usefulness and limitations of microvessel density measurement.
    Int J Urol. 2015 Sep 9. doi: 10.1111/iju.12947.
    PubMed     Text format    


    August 2015
  40. FUJIMOTO N
    Novel agents for castration-resistant prostate cancer: Early experience and beyond.
    Int J Urol. 2015 Aug 27. doi: 10.1111/iju.12907.
    PubMed     Text format     Abstract available


  41. MEARINI L
    Editorial Comment to Reassessment of the risk factors for biochemical recurrence in D'Amico intermediate-risk prostate cancer treated using radical prostatectomy.
    Int J Urol. 2015 Aug 25. doi: 10.1111/iju.12904.
    PubMed     Text format    


  42. HISASUE SI
    Contemporary perspective and management of testosterone deficiency: Modifiable factors and variable management.
    Int J Urol. 2015 Aug 25. doi: 10.1111/iju.12880.
    PubMed     Text format     Abstract available


  43. NARITA S, Mitsuzuka K, Tsuchiya N, Koie T, et al
    Reassessment of the risk factors for biochemical recurrence in D'Amico intermediate-risk prostate cancer treated using radical prostatectomy.
    Int J Urol. 2015 Aug 20. doi: 10.1111/iju.12898.
    PubMed     Text format     Abstract available


  44. SHOJI S, Nakano M, Fujikawa H, Endo K, et al
    Urethra-sparing high-intensity focused ultrasound for localized prostate cancer: Functional and oncological outcomes.
    Int J Urol. 2015 Aug 6. doi: 10.1111/iju.12876.
    PubMed     Text format     Abstract available


  45. INAMOTO T, Azuma H
    Editorial Comment to Urethra-sparing high-intensity focused ultrasound for localized prostate cancer: Functional and oncological outcomes.
    Int J Urol. 2015 Aug 6. doi: 10.1111/iju.12894.
    PubMed     Text format    


    July 2015
  46. WINTER A
    Editorial Comment to Advances in sentinel node dissection in prostate cancer from a technical perspective.
    Int J Urol. 2015 Jul 26. doi: 10.1111/iju.12879.
    PubMed     Text format    


  47. KOBAYASHI T
    Editorial Comment to MicroRNA-205 inhibits cancer cell migration and invasion via modulation of centromere protein F regulating pathways in prostate cancer.
    Int J Urol. 2015 Jul 26. doi: 10.1111/iju.12883.
    PubMed     Text format    


  48. ACAR C, Kleinjan GH, van den Berg NS, Wit EM, et al
    Advances in sentinel node dissection in prostate cancer from a technical perspective.
    Int J Urol. 2015 Jul 14. doi: 10.1111/iju.12863.
    PubMed     Text format     Abstract available


  49. MIYATA Y, Sakai H
    Reconsideration of the clinical and histopathological significance of angiogenesis in prostate cancer: Usefulness and limitations of microvessel density measurement.
    Int J Urol. 2015 Jul 7. doi: 10.1111/iju.12840.
    PubMed     Text format     Abstract available


  50. VAN BRUWAENE S, Murphy DG
    Editorial Comment to Current use of active surveillance for localized prostate cancer: A nationwide survey in Japan.
    Int J Urol. 2015 Jul 5. doi: 10.1111/iju.12881.
    PubMed     Text format    


    June 2015
  51. VAN SOEST RJ
    Editorial Comment to High neutrophil-to-lymphocyte ratio predicts poor clinical outcome in patients with castration-resistant prostate cancer treated with docetaxel chemotherapy.
    Int J Urol. 2015 Jun 24. doi: 10.1111/iju.12856.
    PubMed     Text format    


  52. YAO A, Sejima T, Iwamoto H, Masago T, et al
    High neutrophil-to-lymphocyte ratio predicts poor clinical outcome in patients with castration-resistant prostate cancer treated with docetaxel chemotherapy.
    Int J Urol. 2015 Jun 18. doi: 10.1111/iju.12839.
    PubMed     Text format     Abstract available


  53. NISHIKAWA R, Goto Y, Kurozumi A, Matsushita R, et al
    MicroRNA-205 inhibits cancer cell migration and invasion via modulation of centromere protein F regulating pathways in prostate cancer.
    Int J Urol. 2015 Jun 7. doi: 10.1111/iju.12829.
    PubMed     Text format     Abstract available


    May 2015
  54. STAMATIOU KN
    Editorial Comment from Dr Stamatiou to Clinical outcomes of prostate cancer patients in Yokosuka City, Japan: A comparative study between cases detected by prostate-specific antigen-based screening in Yokosuka and those detected by other means.
    Int J Urol. 2015 May 23. doi: 10.1111/iju.12810.
    PubMed     Text format    


  55. IZUMI K
    Editorial Comment from Dr Izumi to Clinical outcomes of prostate cancer patients in Yokosuka City, Japan: A comparative study between cases detected by prostate-specific antigen-based screening in Yokosuka and those detected by other means.
    Int J Urol. 2015 May 23. doi: 10.1111/iju.12807.
    PubMed     Text format    


  56. SAKAI N, Taguri M, Kobayashi K, Noguchi S, et al
    Clinical outcomes of prostate cancer patients in Yokosuka City, Japan: A comparative study between cases detected by prostate-specific antigen-based screening in Yokosuka and those detected by other means.
    Int J Urol. 2015 May 23. doi: 10.1111/iju.12806.
    PubMed     Text format     Abstract available


  57. MITSUZUKA K, Koga H, Sugimoto M, Arai Y, et al
    Current use of active surveillance for localized prostate cancer: A nationwide survey in Japan.
    Int J Urol. 2015 May 10. doi: 10.1111/iju.12813.
    PubMed     Text format     Abstract available


  58. SCHIFFMANN J, Beyer B, Tennstedt P, Boehm K, et al
    Oncological outcome after radical prostatectomy: Marital status does not make a difference.
    Int J Urol. 2015;22:484-9.
    PubMed     Text format     Abstract available


  59. SKARECKY D
    Editorial Comment from Mr Skarecky to Comparative investigation on clinical outcomes of robot-assisted radical prostatectomy between experienced open prostatic surgeons and novice open surgeons in a laparoscopically naive center with a limited caseloa
    Int J Urol. 2015;22:476.
    PubMed     Text format    


  60. SHIROKI R
    Editorial Comment from Dr Shiroki to Comparative investigation on clinical outcomes of robot-assisted radical prostatectomy between experienced open prostatic surgeons and novice open surgeons in a laparoscopically naive center with a limited caseload
    Int J Urol. 2015;22:475.
    PubMed     Text format    


  61. SUMITOMO M, Kanao K, Kato Y, Yoshizawa T, et al
    Comparative investigation on clinical outcomes of robot-assisted radical prostatectomy between experienced open prostatic surgeons and novice open surgeons in a laparoscopically naive center with a limited caseload.
    Int J Urol. 2015;22:469-74.
    PubMed     Text format     Abstract available


    April 2015
  62. SATO YT
    Editorial comment to Prostate-specific antigen level, stage or Gleason score: which is best for predicting outcomes after radical prostatectomy and does it vary by the outcome being measured? Results from Shared Equal Access Regional Cancer Hospital d
    Int J Urol. 2015;22:366-7.
    PubMed     Text format    


  63. MITHAL P, Howard LE, Aronson WJ, Kane CJ, et al
    Prostate-specific antigen level, stage or Gleason score: which is best for predicting outcomes after radical prostatectomy, and does it vary by the outcome being measured? Results from Shared Equal Access Regional Cancer Hospital database.
    Int J Urol. 2015;22:362-6.
    PubMed     Text format     Abstract available


    March 2015
  64. ROEHRBORN CG, Casabe A, Glina S, Sorsaburu S, et al
    Treatment satisfaction and clinically meaningful symptom improvement in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia: Secondary results from a 6-month, randomized, double-blind study compari
    Int J Urol. 2015 Mar 31. doi: 10.1111/iju.12741.
    PubMed     Text format     Abstract available


  65. ETO M
    IJU this issue.
    Int J Urol. 2015;22:241.
    PubMed     Text format    


  66. NAMIKI S
    Editorial comment to International Prostate Symptom Score is a predictive factor of lower urinary tract symptoms after radical prostatectomy.
    Int J Urol. 2015;22:287.
    PubMed     Text format    


  67. BAYOUD Y, de la Taille A, Ouzzane A, Ploussard G, et al
    International Prostate Symptom Score is a predictive factor of lower urinary tract symptoms after radical prostatectomy.
    Int J Urol. 2015;22:283-7.
    PubMed     Text format     Abstract available


  68. YUMIOKA T, Iwamoto H, Masago T, Morizane S, et al
    Robot-assisted radical prostatectomy in an initial Japanese series: the impact of prior abdominal surgery on surgical outcomes.
    Int J Urol. 2015;22:278-82.
    PubMed     Text format     Abstract available


  69. MATSUYAMA H, Matsumoto H, Nagao K, Harada N, et al
    Running suture versus interrupted suture for vesicourethral anastomosis in retropubic radical prostatectomy: a randomized study.
    Int J Urol. 2015;22:271-7.
    PubMed     Text format     Abstract available


    February 2015
  70. EGAWA S
    IJU this issue.
    Int J Urol. 2015;22:139.
    PubMed     Text format    


  71. SIVARAMAN A, Sanchez-Salas R, Barret E, Ahallal Y, et al
    Transperineal template-guided mapping biopsy of the prostate.
    Int J Urol. 2015;22:146-51.
    PubMed     Text format     Abstract available


  72. TSUZUKI T
    Intraductal carcinoma of the prostate: a comprehensive and updated review.
    Int J Urol. 2015;22:140-5.
    PubMed     Text format     Abstract available


  73. HASHIMOTO T, Yoshioka K, Nagao G, Nakagami Y, et al
    Prediction of biochemical recurrence after robot-assisted radical prostatectomy: analysis of 784 Japanese patients.
    Int J Urol. 2015;22:188-93.
    PubMed     Text format     Abstract available


  74. SHOJI S, Hiraiwa S, Endo J, Hashida K, et al
    Manually controlled targeted prostate biopsy with real-time fusion imaging of multiparametric magnetic resonance imaging and transrectal ultrasound: an early experience.
    Int J Urol. 2015;22:173-8.
    PubMed     Text format     Abstract available


  75. SHOJI S
    Response to editorial comment to Manually controlled targeted prostate biopsy with real-time fusion imaging of multiparametric magnetic resonance imaging and transrectal ultrasound: an early experience.
    Int J Urol. 2015;22:179-80.
    PubMed     Text format    


  76. TELONIS D, Mouraviev V
    Editorial comment to Manually controlled targeted prostate biopsy with real-time fusion imaging of multiparametric magnetic resonance imaging and transrectal ultrasound: an early experience.
    Int J Urol. 2015;22:178-9.
    PubMed     Text format    


  77. SHIMBO M
    Editorial comment to Prediction of biochemical recurrence after robot-assisted radical prostatectomy: analysis of 784 Japanese patients.
    Int J Urol. 2015;22:193-4.
    PubMed     Text format    


  78. MITSUZUKA K
    Editorial comment to Transperineal template-guided mapping biopsy of the prostate.
    Int J Urol. 2015;22:152.
    PubMed     Text format    


    January 2015
  79. KADONO Y
    Editorial Comment from Dr Kadono to Anatomical dimensions using preoperative magnetic resonance imaging: impact on the learning curve of robot-assisted laparoscopic prostatectomy.
    Int J Urol. 2015;22:80-1.
    PubMed     Text format    


  80. TEO XL, Lim SK
    Editorial Comment from Dr Teo and Dr Lim to Anatomical dimensions using preoperative magnetic resonance imaging: impact on the learning curve of robot-assisted laparoscopic prostatectomy.
    Int J Urol. 2015;22:79-80.
    PubMed     Text format    


  81. YAO A, Iwamoto H, Masago T, Morizane S, et al
    Anatomical dimensions using preoperative magnetic resonance imaging: impact on the learning curve of robot-assisted laparoscopic prostatectomy.
    Int J Urol. 2015;22:74-9.
    PubMed     Text format     Abstract available


  82. TERADA T
    Primary small cell carcinoma of prostate without immunoreactive neuroendocrine proteins but with expressions of KIT and platelet-derived growth factor-alpha.
    Int J Urol. 2015;22:122-4.
    PubMed     Text format     Abstract available


    September 2014
  83. SHOJI S, Tonooka A, Hashimoto A, Nakamoto M, et al
    Time-dependent change of blood flow in the prostate treated with high-intensity focused ultrasound.
    Int J Urol. 2014;21:942-5.
    PubMed     Text format     Abstract available


  84. SHIMBO M, Hattori K, Endo F, Matsushita K, et al
    Modified anterior approach to the bladder neck: simple and reproducible procedure for anterior bladder neck transection during robot-assisted radical prostatectomy.
    Int J Urol. 2014;21:946-8.
    PubMed     Text format     Abstract available


  85. CHOO MS, Cho SY, Jeong CW, Lee SB, et al
    Predictors of positive surgical margins and their location in Korean men undergoing radical prostatectomy.
    Int J Urol. 2014;21:894-8.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: